Exploring Sodium Glucose Co-Transporter-2 (SGLT2) Inhibitors for Organ Protection in COVID-19
Review
[키워드] Admission
advanced respiratory support
approach
approved
Canagliflozin
cardiovascular
cardiovascular disease
Chronic kidney disease
clinical development
clinical trial
Clinical use
Coronavirus disease 2019
COVID-19
COVID-19 patient
Cytokine storm
Dapagliflozin
diabetes
Diabetic
effort
Empagliflozin
Factor
faster
Glucose
include
Inflammatory
inhibitor
kidney
Ligand
lung
Mortality
organ
organ function
organ support
outcome
pandemic
potential benefit
preclinical data
PROTECT
protection
receiving
renal
replacing
Repurposed drug
Respiratory failure
risk
severe COVID-19
SGLT2
shown
sodium
Spread
Support
Therapies
therapy
thought
thromboembolic complication
Vaccine
viral replication
[DOI] 10.3390/jcm9072030 PMC 바로가기 [Article Type] Review
[DOI] 10.3390/jcm9072030 PMC 바로가기 [Article Type] Review